Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism.

Krishnan V, Ma YL, Chen CZ, Thorne N, Bullock H, Tawa G, Javella-Cauley C, Chu S, Li W, Kohn W, Adrian MD, Benson C, Liu L, Sato M, Zheng W, Pilon AM, Yang NN, Bryant HU.

Br J Pharmacol. 2018 Jan;175(2):262-271. doi: 10.1111/bph.14028. Epub 2017 Nov 28.

2.

Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.

Ma YL, Hamang M, Lucchesi J, Bivi N, Zeng Q, Adrian MD, Raines SE, Li J, Kuhstoss SA, Obungu V, Bryant HU, Krishnan V.

Bone. 2017 Apr;97:20-28. doi: 10.1016/j.bone.2016.12.003. Epub 2016 Dec 8.

PMID:
27939957
3.

Vitamin D and/or calcium deficient diets may differentially affect muscle fiber neuromuscular junction innervation.

Gifondorwa DJ, Thompson TD, Wiley J, Culver AE, Shetler PK, Rocha GV, Ma YL, Krishnan V, Bryant HU.

Muscle Nerve. 2016 Dec;54(6):1120-1132. doi: 10.1002/mus.25146. Epub 2016 Oct 1.

PMID:
27074419
4.

Molecular targets of androgen signaling that characterize skeletal muscle recovery and regeneration.

MacKrell JG, Yaden BC, Bullock H, Chen K, Shetler P, Bryant HU, Krishnan V.

Nucl Recept Signal. 2015 Oct 7;13:e005. doi: 10.1621/nrs.13005. eCollection 2015.

5.

Follistatin: a novel therapeutic for the improvement of muscle regeneration.

Yaden BC, Croy JE, Wang Y, Wilson JM, Datta-Mannan A, Shetler P, Milner A, Bryant HU, Andrews J, Dai G, Krishnan V.

J Pharmacol Exp Ther. 2014 May;349(2):355-71. doi: 10.1124/jpet.113.211169. Epub 2014 Mar 13.

PMID:
24627466
6.

Hydrophobic Interactions Improve Selectivity to ERĪ± for Ben-zothiophene SERMs.

Chalmers MJ, Wang Y, Novick S, Sato M, Bryant HU, Montrose-Rafizdeh C, Griffin PR, Dodge JA.

ACS Med Chem Lett. 2012 Mar 8;3(3):207-210.

7.

Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats.

Ma YL, Zeng QQ, Porras LL, Harvey A, Moore TL, Shelbourn TL, Dalsky GP, Wronski TJ, Aguirre JI, Bryant HU, Sato M.

Endocrinology. 2011 May;152(5):1767-78. doi: 10.1210/en.2010-1112. Epub 2011 Feb 22.

PMID:
21343258
8.

A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia.

Sato M, Lu J, Iturria S, Stayrook KR, Burris LL, Zeng QQ, Schmidt A, Barr RJ, Montrose-Rafizadeh C, Bryant HU, Ma YL.

J Bone Miner Res. 2010 Jun;25(6):1326-36. doi: 10.1002/jbmr.15.

9.

The selective oestrogen receptor modulator, LY362321, is not neuroprotective in a rat model of transient focal ischaemia.

Farr TD, Carswell HV, McCann DJ, Sato M, Bryant HU, Dodge JA, Macrae IM.

J Neuroendocrinol. 2008 Mar;20(3):366-74. doi: 10.1111/j.1365-2826.2008.01648.x. Epub 2008 Jan 15.

PMID:
18208545
10.

Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor.

Kulkarni NH, Wei T, Kumar A, Dow ER, Stewart TR, Shou J, N'cho M, Sterchi DL, Gitter BD, Higgs RE, Halladay DL, Engler TA, Martin TJ, Bryant HU, Ma YL, Onyia JE.

J Cell Biochem. 2007 Dec 15;102(6):1504-18.

PMID:
17520664
11.

Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety.

Richardson TI, Frank SA, Wang M, Clarke CA, Jones SA, Ying BP, Kohlman DT, Wallace OB, Shepherd TA, Dally RD, Palkowitz AD, Geiser AG, Bryant HU, Henck JW, Cohen IR, Rudmann DG, McCann DJ, Coutant DE, Oldham SW, Hummel CW, Fong KC, Hinklin R, Lewis G, Tian H, Dodge JA.

Bioorg Med Chem Lett. 2007 Jul 1;17(13):3544-9. Epub 2007 Apr 24.

PMID:
17482463
12.

DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids.

Wei T, Geiser AG, Qian HR, Su C, Helvering LM, Kulkarini NH, Shou J, N'Cho M, Bryant HU, Onyia JE.

BMC Womens Health. 2007 Apr 2;7:5.

13.

Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.

Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL.

J Bone Miner Res. 2006 Jun;21(6):910-20.

14.

Regulation of bone mass by Wnt signaling.

Krishnan V, Bryant HU, Macdougald OA.

J Clin Invest. 2006 May;116(5):1202-9. Review.

15.

A selective estrogen receptor modulator for the treatment of hot flushes.

Wallace OB, Lauwers KS, Dodge JA, May SA, Calvin JR, Hinklin R, Bryant HU, Shetler PK, Adrian MD, Geiser AG, Sato M, Burris TP.

J Med Chem. 2006 Feb 9;49(3):843-6.

PMID:
16451049
16.

A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.

Hummel CW, Geiser AG, Bryant HU, Cohen IR, Dally RD, Fong KC, Frank SA, Hinklin R, Jones SA, Lewis G, McCann DJ, Rudmann DG, Shepherd TA, Tian H, Wallace OB, Wang M, Wang Y, Dodge JA.

J Med Chem. 2005 Nov 3;48(22):6772-5.

PMID:
16250633
17.

Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis.

Chintalacharuvu S, Evans GF, Shih C, Bryant HU, Sandusky GE, Zuckerman SH.

Clin Exp Rheumatol. 2005 Jul-Aug;23(4):438-46.

PMID:
16095110
18.

Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene.

Helvering LM, Liu R, Kulkarni NH, Wei T, Chen P, Huang S, Lawrence F, Halladay DL, Miles RR, Ambrose EM, Sato M, Ma YL, Frolik CA, Dow ER, Bryant HU, Onyia JE.

Mol Pharmacol. 2005 Nov;68(5):1225-38. Epub 2005 Aug 3.

PMID:
16079270
19.

A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation.

Geiser AG, Hummel CW, Draper MW, Henck JW, Cohen IR, Rudmann DG, Donnelly KB, Adrian MD, Shepherd TA, Wallace OB, McCann DJ, Oldham SW, Bryant HU, Sato M, Dodge JA.

Endocrinology. 2005 Oct;146(10):4524-35. Epub 2005 Jul 7.

PMID:
16002528
20.

Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.

Ma YL, Bryant HU, Zeng Q, Schmidt A, Jee WS, Sato M.

J Bone Miner Metab. 2005;23 Suppl:62-8.

PMID:
15984416
21.

Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray.

Onyia JE, Helvering LM, Gelbert L, Wei T, Huang S, Chen P, Dow ER, Maran A, Zhang M, Lotinun S, Lin X, Halladay DL, Miles RR, Kulkarni NH, Ambrose EM, Ma YL, Frolik CA, Sato M, Bryant HU, Turner RT.

J Cell Biochem. 2005 May 15;95(2):403-18.

PMID:
15779007
22.

Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus.

Helvering LM, Adrian MD, Geiser AG, Estrem ST, Wei T, Huang S, Chen P, Dow ER, Calley JN, Dodge JA, Grese TA, Jones SA, Halladay DL, Miles RR, Onyia JE, Ma YL, Sato M, Bryant HU.

Biol Reprod. 2005 Apr;72(4):830-41. Epub 2004 Dec 1.

PMID:
15576828
23.

The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist.

Krishnan V, Bullock HA, Yaden BC, Liu M, Barr RJ, Montrose-Rafizadeh C, Chen K, Dodge JA, Bryant HU.

Mol Pharmacol. 2005 Mar;67(3):744-8. Epub 2004 Nov 22.

PMID:
15557561
24.

Benzothiophene and naphthalene derived constrained SERMs.

Wallace OB, Bryant HU, Shetler PK, Adrian MD, Geiser AG.

Bioorg Med Chem Lett. 2004 Oct 18;14(20):5103-6.

PMID:
15380208
25.

Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action.

Sporn MB, Dowsett SA, Mershon J, Bryant HU.

Clin Ther. 2004 Jun;26(6):830-40. Review.

PMID:
15262454
26.

Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.

Onyia JE, Galvin RJ, Ma YL, Halladay DL, Miles RR, Yang X, Fuson T, Cain RL, Zeng QQ, Chandrasekhar S, Emkey R, Xu Y, Thirunavukkarasu K, Bryant HU, Martin TJ.

J Pharmacol Exp Ther. 2004 Apr;309(1):369-79. Epub 2004 Jan 12.

PMID:
14718597
27.

B-ring unsaturated estrogens: biological evaluation of 17alpha-Dihydroequilein and novel B-Nor-6-thiaequilenins as tissue selective estrogens.

Lugar CW 3rd, Magee D, Adrian MD, Shetler P, Bryant HU, Dodge JA.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4281-4.

PMID:
14643309
28.

Central and peripheral temperature changes in sheep following ovariectomy.

MacLeay JM, Lehmer E, Enns RM, Mallinckrodt C, Bryant HU, Turner AS.

Maturitas. 2003 Nov 20;46(3):231-8.

PMID:
14585527
29.

New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.

Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M.

Endocrinology. 2003 May;144(5):2008-15.

PMID:
12697709
30.

Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats.

Ma YL, Bryant HU, Zeng Q, Palkowitz A, Jee WS, Turner CH, Sato M.

J Bone Miner Res. 2002 Dec;17(12):2256-64.

31.

Selective estrogen receptor modulators.

Bryant HU.

Rev Endocr Metab Disord. 2002 Sep;3(3):231-41. Review. No abstract available.

PMID:
12215718
32.

Selective estrogen receptor modulators: tissue selectivity and differential uterine effects.

Silfen SL, Ciaccia AV, Bryant HU.

Climacteric. 1999 Dec;2(4):268-83. Review.

PMID:
11910661
33.

Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

Suh N, Glasebrook AL, Palkowitz AD, Bryant HU, Burris LL, Starling JJ, Pearce HL, Williams C, Peer C, Wang Y, Sporn MB.

Cancer Res. 2001 Dec 1;61(23):8412-5.

34.

Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation.

Bryant HU.

Rev Endocr Metab Disord. 2001 Jan;2(1):129-38. Review.

PMID:
11704975
35.

Photochemical synthesis of N-arylbenzophenanthridine selective estrogen receptor modulators (serms).

Grese TA, Adrian MD, Phillips DL, Shetler PK, Short LL, Glasebrook AL, Bryant HU.

J Med Chem. 2001 Aug 16;44(17):2857-60.

PMID:
11495597
36.

The effect of raloxifene on coronary arteries in aged ovariectomized ewes.

Gaynor JS, Monnet E, Selzman C, Parker D, Kaufman L, Bryant HU, Mallinckrodt C, Wrigley R, Whitehill T, Turner AS.

J Vet Pharmacol Ther. 2000 Jun;23(3):175-9.

PMID:
11110106
37.

Mechanism of action of estrogens and selective estrogen receptor modulators.

Krishnan V, Heath H, Bryant HU.

Vitam Horm. 2000;60:123-47. Review.

PMID:
11037623
38.

[Raloxifene mimics the effect of estrogen on bone].

Bryant HU, Fukuyama T, Nakazawa T.

Tanpakushitsu Kakusan Koso. 2000 Apr;45(6 Suppl):1102-8. Review. Japanese. No abstract available.

PMID:
10771680
39.

Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats.

Wu X, Glinn MA, Ostrowski NL, Su Y, Ni B, Cole HW, Bryant HU, Paul SM.

Brain Res. 1999 Nov 13;847(1):98-104.

PMID:
10564741
40.

An estrogen receptor basis for raloxifene action in bone.

Bryant HU, Glasebrook AL, Yang NN, Sato M.

J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):37-44. Review.

PMID:
10418979
41.

Emerging therapies for the prevention or treatment of postmenopausal osteoporosis.

Sato M, Grese TA, Dodge JA, Bryant HU, Turner CH.

J Med Chem. 1999 Jan 14;42(1):1-24. Review. No abstract available.

PMID:
9888829
42.

LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.

Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU.

J Pharmacol Exp Ther. 1998 Oct;287(1):1-7.

PMID:
9765314
43.

Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene.

Turner RT, Evans GL, Sluka JP, Adrian MD, Bryant HU, Turner CH, Sato M.

Endocrinology. 1998 Sep;139(9):3712-20.

PMID:
9724022
44.

Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys.

Bryant HU, Kauffman RF, Iversen P, Cox DA, Mitlak BH, Heath H 3rd.

J Clin Endocrinol Metab. 1998 Aug;83(8):3001-4. No abstract available.

PMID:
9709984
45.
46.

Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.

Grese TA, Pennington LD, Sluka JP, Adrian MD, Cole HW, Fuson TR, Magee DE, Phillips DL, Rowley ER, Shetler PK, Short LL, Venugopalan M, Yang NN, Sato M, Glasebrook AL, Bryant HU.

J Med Chem. 1998 Apr 9;41(8):1272-83.

PMID:
9548817
47.

Molecular determinants of tissue selectivity in estrogen receptor modulators.

Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA.

Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14105-10.

48.

Selective estrogen receptor modulators: an alternative to hormone replacement therapy.

Bryant HU, Dere WH.

Proc Soc Exp Biol Med. 1998 Jan;217(1):45-52. Review.

PMID:
9421206
49.

Selective estrogen receptor modulators and postmenopausal women's health.

Hol T, Cox MB, Bryant HU, Draper MW.

J Womens Health. 1997 Oct;6(5):523-31. Review.

PMID:
9356975
50.

Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.

Palkowitz AD, Glasebrook AL, Thrasher KJ, Hauser KL, Short LL, Phillips DL, Muehl BS, Sato M, Shetler PK, Cullinan GJ, Pell TR, Bryant HU.

J Med Chem. 1997 May 9;40(10):1407-16.

PMID:
9154963

Supplemental Content

Loading ...
Support Center